Overview

EMERALD (Emergency Medicine Cardiovascular Risk Assessment for Lipid Disorders)

Status:
Not yet recruiting
Trial end date:
2023-05-01
Target enrollment:
Participant gender:
Summary
The EMERALD intervention involves 1) ordering an Emergency Department (ED) lipid panel, 2) calculating 10-year Atherosclerotic cardiovascular disease (ASCVD) risk using the Pooled Cohort Equations, 3) prescribing a moderate- or high-intensity statin if applicable, and 4) referring patients to outpatient care (primary care, preventive cardiology, or general cardiology, depending on risk level).
Phase:
Phase 4
Details
Lead Sponsor:
Wake Forest University Health Sciences
Treatments:
Rosuvastatin Calcium